BioCina to expand mRNA vaccines capabilities
Biotechnology company BioCina is expanding the capabilities of its Australian biologics facility (pictured), broadening its capabilities to manufacture mRNA-based vaccines and therapies. The factory, formerly owned by vaccines manufacturer Pfizer, is to employ a range of technologies from associated companies Cytiva and others associated with American medical group of companies Danaher, as well as collaborater…
Details










